2.04
Gri Bio Inc Aktie (GRI) Neueste Nachrichten
Is GRI Bio Inc. a good long term investmentFree Trend-Following Techniques - Autocar Professional
What analysts say about GRI Bio Inc. stockConsistent high-performance stocks - jammulinksnews.com
GRI Bio Inc. Stock Analysis and ForecastSuperior trading gains - jammulinksnews.com
What drives GRI Bio Inc. stock priceOver 200% growth - jammulinksnews.com
GRI Bio Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
GRI Bio CEO Unveils Strategic Vision for Revolutionary NKT Cell Platform in Exclusive Interview - Stock Titan
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
JTC Team Announces Participating Line Up for the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference - Knoxville News Sentinel
AI in Retail and Consumer Goods5x Profit Potential - Newser
COLX(colossuscoinxt) Price TodayFast Growing Stocks - Newser
What makes GRI Bio Inc. stock price move sharplyWatchlist Winner Update - Newser
How GRI Bio Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
Why Eli Lilly and Company stock attracts strong analyst attentionSmart Money Signals - Newser
Why GRI Bio Inc. stock attracts strong analyst attentionFree Growth Investment Group - Newser
GRI Bio stock holds Buy rating at H.C. Wainwright as Phase 2a trial completes enrollment - Investing.com
GRI Bio, Inc. Completes Patient Enrollment in Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis, Interim Results Show Safety and Tolerability - Nasdaq
GRI Bio's GRI-0621: A Breakthrough in IPF with Near-Term Catalysts and a Growing Market - AInvest
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
GRI Bio, Inc. Reports Positive 6-Week Interim Safety Results from its Ongoing Phase 2a Study Evaluating GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis - MarketScreener
Q2 Earnings Estimate for GRI Bio Issued By HC Wainwright - Defense World
Kalkine : GRI Bio Advancing in the Nasdaq Composite Healthcare Space - Kalkine Media
GRI Bio (NASDAQ:GRI) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for GRI Bio (NASDAQ:GRI) - Defense World
GRI Bio’s (GRI) Buy Rating Reiterated at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Given “Buy” Rating at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Earns Buy Rating from HC Wainwright - Defense World
GRI Bio’s (GRI) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):